{"id":389023,"date":"2024-12-09T00:00:00","date_gmt":"2024-12-09T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfhe0001-2024-biopharma-hemophilia-a-inhibitors-disease-landscape-forecast-g7-2024\/"},"modified":"2026-03-31T10:27:47","modified_gmt":"2026-03-31T10:27:47","slug":"dlsfhe0001-2024-biopharma-hemophilia-a-inhibitors-disease-landscape-forecast-g7-2024","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfhe0001-2024-biopharma-hemophilia-a-inhibitors-disease-landscape-forecast-g7-2024\/","title":{"rendered":"Hemophilia A +\/- Inhibitors | Disease Landscape &#038; Forecast | G7 | 2024"},"content":{"rendered":"<p>The acceptance of Roche \/ Chugai\u2019s nonfactor bispecific antibody Hemlibra as a key treatment for hemophilia A has changed the treatment landscape. Hemlibra has been transformative for many inhibitor patients who were on bypass agent prophylaxis, providing improved treatment outcomes. It is also a more-convenient prophylaxis option for noninhibitor patients due to its lower dosing frequency and SC administration. The next 10 years will be exciting for the hemophilia A (with and without inhibitors) therapy market owing to the entry of an extended half-life factor VIII product (Sanofi \/ Sobi\u2019s Altuviiio \/ Altuvoct), several nonfactor agents (Sanofi\u2019s fitusiran, Pfizer\u2019s marstacimab, and Novo Nordisk\u2019s concizumab and Mim8), and gene therapies (BioMarin\u2019s Roctavian, Pfizer \/ Sangamo Therapeutics\u2019 giroctocogene fitelparvovec). Supported by insights from thought leaders, we assess the impact of new drugs on the treatment of hemophilia A.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul>\n<li>What is the current treatment landscape for hemophilia A? What are physicians\u2019 experience and satisfaction levels with key therapies?<\/li>\n<li>How has Hemlibra changed the treatment landscape for hemophilia A for patients with and without inhibitors?<\/li>\n<li>What clinical roles will Altuviiio, concizumab, fitusiran, marstacimab, Mim8, and gene therapy play in the evolving hemophilia A treatment landscape?<\/li>\n<li>How will the management of patients with and without inhibitors change when new treatment options become available?<\/li>\n<li>How will the factor VIII concentrate market evolve?<\/li>\n<li>How will nonfactor treatment options impact the multitude of brands competing for patient share?<\/li>\n<\/ul>\n<p><strong>Geography:<\/strong> United States, EU5, Japan<\/p>\n<p><strong>P<\/strong><strong>rimary research:<\/strong> 19 country-specific interviews with thought-leading hematologists and supported by survey data collected for this and other Clarivate research<\/p>\n<p><strong>E<\/strong><strong>pidemiology:<\/strong> Diagnosed prevalence of hemophilia A +\/-inhibitors by country, population segmentation by disease severity and inhibitor titer<\/p>\n<p><strong>Forecast:<\/strong> 10-year, annualized, drug-level sales and patient share of key hemophilia A therapies through 2033, segmented by brands and epidemiological subpopulations<\/p>\n<p><strong>Drug treatments:<\/strong> Coverage of select current and emerging therapies<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Key features<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.<\/p>\n<p>Disease Landscape &#038; Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.<\/p>\n","protected":false},"template":"","class_list":["post-389023","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hemophilia","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389023","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389023\/revisions"}],"predecessor-version":[{"id":575875,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389023\/revisions\/575875"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389023"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}